GSK and Hansoh press on despite Pfizer’s exit
A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.
Avenzo follows Bristol’s lead
The private group taps DualityBio for an EGFR x HER3 ADC.
Elevation brings Synaffix on board in HER3
But the group is going up against the likes of Merck/Daiichi, Bristol Myers Squibb and BioNTech.
A fourth challenger from DualityBio and BioNTech
Yet more data validate B7-H3, and put MediLink in the deal-making frame.
Gilead and GSK nab early ADCs
Gilead links up with Tubulis, while GSK taps BioNTech’s partner DualityBio.
Two oncology floats to end the summer break
Bicara and DualityBio will soon test market appetite for new oncology issues.
A Prelude to a Lilly duel
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
